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Vascular calcification: Hardening 
of the evidence
SM Moe1
In the past several years, basic-science studies have shown that vascular 
calcification is an active, cell-mediated process. It is increased in the 
uremic milieu and with hyperphosphatemia and therefore should 
be preventable. Additional advances in imaging techniques have 
facilitated the diagnosis of arterial calcification, a critical initial step in 
the translation of this knowledge to patient care. 
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In the past ten years we have observed a 
major increase in the number of publica-
tions that examine vascular calcifi cation 
in chronic kidney disease (CKD) patients, 
especially those receiving dialysis. Using 
the limited search terms ‘vascular calci-
fi cation’ and ‘kidney/renal’ in PubMed, 
there were 11 articles in 1995 and 115 in 
2005. Yet this issue is not new; studies in 
the 1970s clearly demonstrated that cal-
cifi cation in the intimal and medial lay-
ers of arteries was increased in patients 
with advanced kidney disease.1 Why has 
there been such an increase in interest in 
this fi eld recently? Th ere are several likely 
reasons. First, advances in basic-science 
research have demonstrated that vascular 
calcifi cation is not just the passive process 
we once thought. Vascular smooth muscle 
cells retain pluripotential capability and 
can transform into osteoblast-like cells. 
Th ese cells, at least in culture, can produce 
bone matrix proteins and will mineralize 
in the presence of calcium and phospho-
rus at levels common in CKD patients. 
Furthermore, uremic serum, oxidized 
proteins, low fetuin-A, interleukin-1, 
and interleukin-6 can all accelerate this 
process2 (Table 1). Observational stud-
ies have also shown these same factors to 
be associated with increased mortality in 
dialysis patients and, in some studies, with 
increased vascular or valvular calcifi ca-
tion.3,4 Second, a major advance in tech-
nology has led to our ability to quantify 
the degree of calcifi cation in a noninva-
sive manner with computed tomography 
(CT) scanners, either electron beam CT 
or multislice CT. Th is has allowed us to 
conduct observational and interventional 
studies that have greatly enhanced our 
understanding of the pathophysiology of 
the calcifi cation process and the extremely 
high incidence of coronary artery, aorta, 
and valvular calcification. Nearly all 
series in dialysis patients from all over the 
world demonstrate that 70% of patients 
have signifi cant calcifi cation of the coro-
nary arteries and aorta, and nearly 50% 
have valvular calcifi cation.5 Even 50% of 
patients new to dialysis have evidence of 
signifi cant coronary artery calcifi cation.6 
Th ird, our once complacent acceptance of 
serum phosphorus levels of 7 mg/dl has 
been replaced by new knowledge that dis-
orders of mineral metabolism and bone 
contribute to morbidity and mortality 
beyond fractures and bone pain. This 
recognition of the systemic nature of this 
problem led Kidney Disease: Improving 
Global Outcomes to coin the new term 
‘CKD–mineral bone disorder’ (CKD–
MBD) to describe the trilogy of abnormal 
biochemistries, bone, and extraskeletal 
calcification, while reserving the term 
‘renal osteodystrophy’ to describe patho-
logy limited to bone.7 Lastly, clinicians 
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now have many new therapeutic options 
to treat CKD–MBD, one of which, sevela-
mer, has been shown to ameliorate coro-
nary artery and aorta calcifi cation in two 
randomized prospective trials.6,8 
How has this new knowledge changed 
the care of our patients? Recent clinical 
practice guidelines have attempted to 
guide the approach and the treatment 
of our patients using evidence ratings. 
Th e Kidney Disease Outcomes Quality 
Initiative bone and mineral guidelines, 
published in 2003, recommended more 
aggressive lowering of serum phospho-
rus calcium × and × phosphorus prod-
uct. Th ese guidelines also opined that 
there were some data, albeit not strong, 
to recommend that the amount of oral 
calcium in the form of phosphate bind-
ers be restricted to 1500 mg per day, 
and that calcium binders not be used in 
dialysis patients with low parathyroid 
hormone or evidence of vascular calci-
fi cation in order to reduce the burden of 
calcifi cation.9 Th ese recommendations 
were based on opinion, with a literature 
review cutoff  of 2001. Th ese guidelines 
also did not detail how to diagnose vas-
cular calcifi cation, or how to quantify the 
severity. Th e Kidney Disease Outcomes 
Quality Initiative cardiovascular guide-
lines, by a separate work group, rec-
ommended that screening for vascular 
calcifi cation should be done, and that, if 
found by plain radiographs, calcifi cation 
at another site should be sought (level 
C  = weak evidence or opinion). Th ese 
guidelines, published in 2005, further 
recommended that if vascular calcifi ca-
tion is present at two or more sites, then 
consideration should be given to pre-
scription of a non-calcium-containing 
phosphate binder (level B = moderately 
strong evidence). Both of these sets of 
guidelines lack defi nitive information 
on the sensitivity, specifi city, and pre-
dictive value of these various noninva-
sive measures of arterial calcifi cation. A 
consensus conference of international 
experts in the fi eld of mineral and bone 
metabolism and vascular calcifi cation, 
held in 2003, concluded that a calcifi -
cation index should be developed.10 It 
was believed that such an index would 
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none of which will be strongly evidenced 
based. First, we can use the presence or 
absence of calcification to guide our 
choice of phosphate binders. Second, 
we can use the presence or absence of 
calcifi cation to educate our patients on 
the need to be compliant with phosphate 
binders, antihypertensives, and intradia-
lytic weight gains (to name a few). Th ird, 
we can use the presence of calcifi cation 
to help prioritize which of the many 
expensive medications to use in our 
patients. Th e latter may be particularly 
important for governments and man-
aged care providers around the world to 
make informed decisions. For example, 
some such entities require hypercalcemia 
to be present in order to justify the use 
of non-calcium-containing phosphate 
binders. Given the disconnect between 
hypercalcemia and vascular calcifi cation, 
using more physiologically relevant cri-
teria may make sense. Most importantly, 
we now have a sound rationale for using 
these noninvasive measures of calcifi ca-
tion to defi ne better criteria for study-
population inclusion in studies that aim 
to reduce vascular calcifi cation. Perhaps 
better-defi ned populations will lead to 
better studies, and, ultimately, the Holy 
Grail of nephrology — a reduction in 
mortality in dialysis patients. 
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Known coronary artery disease
Abnormal bone
Biochemical Hyperphosphatemia
Hypercalcemia
Abnormal parathyroid hormone
Low fetuin-A
Elevated cytokines
Oxidative stress
Low pyrophosphate
Decreased MGP
Decreased BMP-7
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facilitate the ability of a clinician to diag-
nose vascular and valvular calcifi cation 
in order to predict which patients would 
have adverse cardiovascular outcomes. 
Th e conference attendees thought that 
this would be an important fi rst step to 
identify the subset of subjects most likely 
to benefi t from aggressive and, unfortu-
nately, expensive interventions. 
Bellasi and colleagues11 (this issue) 
describe work that is the fi rst step in devel-
oping such a calcification index. They 
performed electron beam CT to quan-
tify coronary artery calcifi cation in 140 
dialysis patients in the United States and 
compared these results with those of tests 
that are less expensive, more commonly 
available, and with lower radiation expo-
sure, including pulse pressure, echocardi-
ography, and plain lateral abdominal fi lm. 
Th ey found a likelihood ratio (95% con-
fi dence interval) of a coronary artery cal-
cifi cation score of ≥100 by electron beam 
CT of 1.79 (1.09, 2.96) for calcifi cation of 
the aorta or mitral valve, and 7.50 (2.89, 
19.5) for a lateral lumbar X-ray score of 
≥7. In contrast, there was no signifi cant 
predictive value of pulse-pressure assess-
ment. Although these results are encour-
aging, it should be emphasized that no 
area under the curve was above 0.8. Th ese 
data represent an important fi rst step to 
aid the clinician in risk stratifi cation of 
vascular calcifi cation in order to guide 
therapy. Th e next study to follow logically 
would be to evaluate combinations of fac-
tors, probably age, duration of dialysis, 
biochemistries, and one of these tests, to 
see whether the positive and negative pre-
dictive values improve. Most important, 
patients must be followed prospectively 
to determine whether this calcifi cation 
index will predict mortality, and whether 
interventions that reduce the index lead 
to improvements in mortality. 
It is this last measure that remains the 
most frustrating to the nephrology com-
munity. Our dialysis patient population 
has dismal survival statistics, worse than 
those for many cancers, and we have 
failed to make a signifi cant impact on 
mortality despite many new advances. 
Importantly, we lack large, prospec-
tive randomized clinical trials to guide 
clinical decision making, a luxury that so 
many other fi elds in medicine enjoy. Why 
is this so? One explanation is that many 
studies are simply underpowered. A sec-
ond explanation is that the population of 
dialysis patients is relatively small com-
pared with that for other diseases, which 
reduces the funding available to conduct 
such studies. Yet another explanation is 
that our patients on dialysis have so many 
problems that we cannot begin to treat 
all in a single study. Th e latter point is 
important, as it is likely that a combina-
tion of interventions will be required to 
reduce mortality. Despite this lack of evi-
dence, we all routinely still provide these 
interventions to our patients, including 
enhancement of dialysis dose, correction 
of anemia, lowering of blood pressure, 
reduction of low-density lipoprotein with 
statins, improvement of glycemic control, 
and reduction of parathyroid hormone, 
because it makes biologic sense to do so.
So what should we do with the 
hardening of the evidence on vascu-
lar calcification? The study by Bellasi 
and colleagues11 suggests that we can 
use simple screening tools to give us a 
roughly 70% chance of predicting sig-
nifi cant coronary artery calcifi cation in 
our dialysis patients. We can then choose 
to use those data in a number of ways, 
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Bisphosphonates prevent 
experimental vascular 
calcification: Treat the bone to 
cure the vessels?
V Persy1, M De Broe1 and M Ketteler2
Bisphosphonates are inhibitors of bone resorption that are widely 
used to treat osteoporosis. Price and colleagues demonstrate that 
ibandronate suppressed the development of uremia-related vascular 
calcification in rats. These findings extend the link between bone 
remodeling and vascular calcification to the context of chronic renal 
failure, opening perspectives toward novel therapeutic strategies.
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Chronic kidney disease is associated with 
a strong increase in cardiovascular risk, 
which is responsible for approximately 
50% of the mortality in the hemodial-
ysis population. Increased vascular 
calcification is a prominent feature of 
vascular disease in uremic patients. 
Coronary calcifi cation is already present 
in young hemodialysis patients and 
shows rapid progression. In addition to 
increased calcifi cation of atherosclerotic 
plaques, patients on dialysis also show 
characteristic calcifi cations of the vascu-
lar tunica media, which also contribute 
signifi cantly to the excess cardiovascular 
mortality observed in uremic patients.1
Price et al.2 (this issue) report that the 
bisphosphonate ibandronate prevents the 
development of vascular calcifi cation in 
rats with adenine-induced chronic renal 
failure maintained on a low-protein diet.
Combination of adenine-induced 
chronic renal failure with a synthetic 
diet with low protein content proved to 
reliably induce media calcifi cation in the 
large arteries of these animals, whereas 
the standard model induces vascular 
calcifi cation only in a subset of animals3 
(V Persy et al., unpublished observations). 
The availability of a reliable model of 
uremia-induced vascular calcifi cation is 
an important asset for future experimen-
tal research into the pathomechanisms 
of pharmacological agents and their 
impact on artery calcifi cation in chronic 
renal failure. Moreover, this fi nding is 
not without its implications for human 
disease: dietary protein restriction is still 
occasionally used in chronic kidney dis-
ease patients in order to slow progression 
of kidney-function deterioration and is 
one of the standard measures imposed on 
dialysis patients to keep phosphate levels 
under control; malnutrition always looms 
around the corner for these patients. So 
maintaining a good nutritional status in 
end-stage renal failure patients is impor-
tant not only to fi ght off  chronic infl am-
mation, but possibly also to limit the 
development of vascular calcifi cation.
Bisphosphonates are pyrophosphate 
analogues resistant to enzymatic hydro-
lysis that are widely used to treat bone 
diseases characterized by increased bone 
resorption, such as osteoporosis, Paget’s 
disease, osteolytic lesions, and hypercal-
cemia associated with multiple myeloma. 
In high doses these compounds physi-
cochemically inhibit mineralization by 
inhibiting the formation and aggregation 
of calcium phosphate crystals and block-
ing the transformation of amorphous 
calcium phosphate to hydroxyapatite. 
However, their therapeutic use depends on 
their inhibition of bone resorption, which 
occurs at low doses that do not aff ect min-
eralization.4 Bisphosphonates increase 
the bone mineral density of osteoporotic 
patients by inhibiting osteoclastic bone 
resorption through several mechanisms: 
they inhibit terminal diff erentiation of 
osteoclasts, induce apoptosis of osteo-
clasts, and decrease osteoclastic activity 
by inhibiting protein prenylation.4
However, bisphosphonates are also 
reported to act on cells of the osteo-
blastic lineage,5 and the eff ect of diff erent 
bisphosphonate compounds on osteo-
blastic cells correlates well with their dif-
ferent potency in vivo.4
The findings reported in this issue2 
extend results previously reported by 
Price’s group showing that bisphospho-
nates can inhibit the development of 
arterial calcifi cation in rats with normal 
renal function treated with warfarin or 
toxic doses of vitamin D,6 and they add 
to the growing body of experimental evi-
dence that links vascular calcifi cation to 
